MX2022001449A - Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. - Google Patents

Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.

Info

Publication number
MX2022001449A
MX2022001449A MX2022001449A MX2022001449A MX2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A MX 2022001449 A MX2022001449 A MX 2022001449A
Authority
MX
Mexico
Prior art keywords
same
methods
ent
human
compositions including
Prior art date
Application number
MX2022001449A
Other languages
English (en)
Spanish (es)
Inventor
Michael Zasloff
Denise Barbut
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of MX2022001449A publication Critical patent/MX2022001449A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022001449A 2019-08-02 2020-07-31 Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. MX2022001449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882358P 2019-08-02 2019-08-02
US202063041031P 2020-06-18 2020-06-18
PCT/US2020/044390 WO2021025973A1 (en) 2019-08-02 2020-07-31 Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same

Publications (1)

Publication Number Publication Date
MX2022001449A true MX2022001449A (es) 2022-04-06

Family

ID=74502413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001449A MX2022001449A (es) 2019-08-02 2020-07-31 Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.

Country Status (7)

Country Link
US (2) US12503485B2 (https=)
EP (1) EP4007764B1 (https=)
JP (1) JP7819094B2 (https=)
CN (1) CN114929724B (https=)
CA (1) CA3149479A1 (https=)
MX (1) MX2022001449A (https=)
WO (1) WO2021025973A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028810A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions and methods for treating brain-gut disorders
WO2021025974A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment
WO2021216399A1 (en) * 2020-04-20 2021-10-28 Enterin, Inc. Pulmonary aminosterol compositions and methods of using the same to treat microbial infections
WO2023146842A1 (en) * 2022-01-25 2023-08-03 Enterin, Inc. C25 r and s isomers of aminosterols and methods of making and using the same
CN119768413A (zh) * 2022-06-29 2025-04-04 因特尔公司 氨基甾醇化合物、氨基甾醇-环糊精制剂和使用它们的方法
CN118085053A (zh) * 2022-11-25 2024-05-28 深圳先进技术研究院 以Inx5基因或以Inx5蛋白作为作用靶点的物质的应用
US12570686B1 (en) 2024-11-15 2026-03-10 BAZ Therapeutics, Inc. Chemical structures that control metabolic elimination of aminosterols
CN119770654A (zh) * 2025-01-08 2025-04-08 南京大学 Parp1抑制剂在制备治疗和/或缓解弗里德赖希氏共济失调的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
WO1994020520A1 (en) 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
AU3512595A (en) 1994-09-13 1996-03-29 Magainin Pharmaceuticals, Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
AU723663C (en) 1995-06-07 2001-11-01 Magainin Pharmaceuticals, Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
WO2009032321A2 (en) * 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
MX367255B (es) 2012-04-20 2019-08-12 Ohr Pharmaceutical Inc Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
EP2934543B1 (en) 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
GB201303589D0 (en) 2013-02-27 2013-04-10 Univ Swansea Compound and method for the treatment of neurodegenerative conditions
GB201316050D0 (en) * 2013-09-10 2013-10-23 Univ Swansea Deuterated compounds
EP3083656A1 (en) * 2013-12-20 2016-10-26 Prevacus Inc. Synthesis of ent-progesterone and intermediates thereof
FR3055802B1 (fr) 2016-09-15 2018-08-24 Virbac Derives amides de squalamine pour le traitement des infections
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
US20230125585A1 (en) 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment
WO2021025974A1 (en) 2019-08-02 2021-02-11 Enterin, Inc. Human squalamine derivatives, related compositions comprising the same, and methods of using the same

Also Published As

Publication number Publication date
EP4007764A4 (en) 2023-08-09
CA3149479A1 (en) 2021-02-11
AU2020324937A1 (en) 2022-03-10
US20260098052A1 (en) 2026-04-09
CN114929724B (zh) 2024-12-10
JP2022543242A (ja) 2022-10-11
EP4007764B1 (en) 2026-01-21
EP4007764A1 (en) 2022-06-08
CN114929724A (zh) 2022-08-19
EP4007764C0 (en) 2026-01-21
WO2021025973A1 (en) 2021-02-11
US12503485B2 (en) 2025-12-23
JP7819094B2 (ja) 2026-02-24
US20230123701A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
CL2021003373A1 (es) Nuevos inhibidores de egfr
CL2020002801A1 (es) Anticuerpos monoclonales contra bcma (divisional de solicitud 201800281).
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
MX2020009347A (es) Picolinamidas como fungicidas.
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
MX2021006977A (es) Anellosomas y metodos de uso.
CR20190566A (es) Inhibidores de quinasay usos de los mismos
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
MX2019009759A (es) Composiciones de peptido estables.
CL2020002217A1 (es) Uso de alcoxipirazoles como inhibidores de la nitrificación
CL2021003228A1 (es) Compuestos tricíclicos y su uso
UY37665A (es) Formas cristalinas de (s)-afoxolaner
CR20220292A (es) Tiofenocarboxamidas sustituidas y sus derivados
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
BR112017018618A2 (pt) odorizante de osmanthus